Fig. 1From: The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisalPatients with episodic migraine: effect of erenumab on monthly migraine days, monthly migraine-specific medication days, and 50% reduction in monthly migraine days from baseline according to prior preventive treatment failures in the STRIVE trial [15] and its open-label extension [16]Back to article page